Drug

Rucaparib

Regulatory activity · MHRA

ClassPARP 1, 2 and 3 inhibitorEmerging researchLate-stage development

Also known as Rubraca.

RxNorm1862579 ChEMBLCHEMBL1173055 ATCL01XK03UNII8237F3U7EH

Research papers

Active clinical trials

Protein targets

Regulatory events

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Phase II Study of Rucaparib and Nivolumab in Patients With Leiomyosarcoma

Clinical trial2026-07-17Results posted · ClinicalTrials.gov

Pan-Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS Sponsored Trials Investigating Nivolumab and Other Cancer Therapies

Clinical trial2026-07-02Results expected Q3 2029 · ClinicalTrials.gov

An Open Label, Multicenter Extension Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella B)

Clinical trial2026-04-28Results expected Q3 2028 · ClinicalTrials.gov

An Open Label, Non-Randomized Multisite Phase II Trial Combining Bevacizumab, Atezolizumab and Rucaparib for the Treatment of Previously Treated Recurrent and Progressive Endometrial Carcinoma

Clinical trial2026-04-13Results posted · ClinicalTrials.gov

A Phase II Study With a Safety lead-in of Nivolumab in Combination With Bevacizumab or in Combination With Bevacizumab and Rucaparib for the Treatment of Relapsed Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer

Clinical trial2026-04-01Results posted · ClinicalTrials.gov

A Phase II, Randomized, Double-Blind Study of the Use of Rucaparib vs. Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer

Clinical trial2026-03-24Results posted · ClinicalTrials.gov

A Phase 2 Study of Nivolumab in Combination With Either Rucaparib, Docetaxel, or Enzalutamide in Men With Castration-resistant Metastatic Prostate Cancer

Clinical trial2026-01-27Results posted · ClinicalTrials.gov

A Phase I Study of Rucaparib Administered Concurrently With Postoperative Radiotherapy in Patients With Triple Negative Breast Cancer With an Incomplete Pathologic Response Following Neoadjuvant Chemotherapy

Clinical trial2025-12-08Results posted · ClinicalTrials.gov

TRITON3: A Multicenter, Randomized, Open Label Phase 3 Study of Rucaparib Versus Physician's Choice of Therapy for Patients With Metastatic Castration Resistant Prostate Cancer Associated With Homologous Recombination Deficiency

Clinical trial2025-07-25Results posted · ClinicalTrials.gov

Rucaparib or Physician's Choice in Metastatic Prostate Cancer.

Research2023-02-16The New England journal of medicine

Drug Safety Update: Rucaparib (Rubraca▼): withdrawal of third-line treatment indication

Regulatory2022-09-26MHRA

Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration.

Research2020-08-14Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Rucaparib

Aliases & brands

Rubraca

RxNorm CUI

1862579

ChEMBL ID

CHEMBL1173055

ATC codes

L01XK03

UNII

8237F3U7EH

Primary mechanism

PARP 1, 2 and 3 inhibitor

Regulatory jurisdictions

mhra

Pharmacology & targets

3 targets

Known molecular targets and mechanisms supported by curated pharmacology databases.

Poly [ADP-ribose] polymerase 1

PARP1 · P09874

INHIBITORPARP 1, 2 and 3 inhibitor

Protein mono-ADP-ribosyltransferase PARP3

PARP3 · Q9Y6F1

INHIBITORPARP 1, 2 and 3 inhibitor

Poly [ADP-ribose] polymerase 2

PARP2 · Q9UGN5

INHIBITORPARP 1, 2 and 3 inhibitor

Regulatory timeline

1 event

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Authorities

MHRA

Total events

mhraMedicines and Healthcare products Regulatory Agency· 1 event

2022-09-26Safety communicationSafety

Drug Safety Update: Rucaparib (Rubraca▼): withdrawal of third-line treatment indication

Evidence ↗

Contains public sector information from the Medicines and Healthcare products Regulatory Agency (MHRA) licensed under the Open Government Licence (OGL v3).

Clinical trials

56 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme

CLINICALTRIALS.GOV · LIVE REGISTRY

registered trials across all phases

LATEST COMPLETION 2026

Active studies

Recruiting

Late-stage (III+)

Completed

Discontinued

PHASE DISTRIBUTIONn = 56

Early Phase 11Phase 19Phase 1 / 211Phase 228Phase 37

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

ATHENA (A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy)

Active, not recruitingPH IIIKey trialpharmaand GmbHn=1,0972030

An Open Label, Multicenter Extension Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella B)

Active, not recruitingPH IIIKey trialHoffmann-La Rochen=1,0002028

CompletedPH IIIpharmaand GmbHn=4052024

Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients

CompletedPH IIINorth Eastern German Society of Gynaecological Oncologyn=422024

CATCH-R: A Rollover Study to Provide Continued Access to Clinical Therapy With Rucaparib

CompletedPH IIIpharmaand GmbHn=342023

Recent completions

Trials that read out recently, adding to the completed evidence base.

An Open Label, Non-Randomized Multisite Phase II Trial Combining Bevacizumab, Atezolizumab and Rucaparib for the Treatment of Previously Treated Recurrent and Progressive Endometrial Carcinoma

CompletedPH IIMedical College of Wisconsinn=302026

A Phase II, Randomized, Double-Blind Study of the Use of Rucaparib vs. Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer

CompletedPH IIUniversity of Colorado, Denvern=792026

CompletedPH IMemorial Sloan Kettering Cancer Centern=312025

Phase I/II Trial of PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers

CompletedPH I/IINational Cancer Institute (NCI)n=102025

A Phase 2 Study of Nivolumab in Combination With Either Rucaparib, Docetaxel, or Enzalutamide in Men With Castration-resistant Metastatic Prostate Cancer

CompletedPH IIBristol-Myers Squibbn=2922025

A Phase II Study of Rucaparib in Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)

CompletedPH IISWOG Cancer Research Networkn=642024

Research activity

2 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time

20202023

Most influential

Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020 · 530 cites

Rucaparib or Physician's Choice in Metastatic Prostate Cancer.

The New England journal of medicine · 2023 · 332 cites

Related diseases

1 conditions

Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.

Active research areas

Prostatic Neoplasms, Castration-Resistant2

Related drugs

3 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Abiraterone

Studied across 2 of the same disease areas as Rucaparib in the shared literature.

2 shared diseases1 shared paper

Docetaxel

Studied across 2 of the same disease areas as Rucaparib in the shared literature.

2 shared diseases1 shared paper

Enzalutamide

Studied across 2 of the same disease areas as Rucaparib in the shared literature.

2 shared diseases1 shared paper

References & data sources

RxNorm (U.S. National Library of Medicine) — drug identity
ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
Europe PMC — research literature
ClinicalTrials.gov — clinical trials
Regulatory event sources are credited in the Regulatory Timeline above.